Guselkumab for the treatment of psoriasis: a 60-week real-life multicenter retrospective experience

Bardazzi, Federico; Viviani, Filippo; Merli, Yuri; Lernia, Vito Di; Peccerillo, Francesca; Conti, Andrea A.; Lasagni, Claudia; Tabanelli, Michela; D’Adamio, Simone; Nuzzo, Sergio Di; Cortellazzi, Chiara; Filippi, Federica

doi:10.1080/14712598.2022.2064216

Cited by 12 publications

(13 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, in VOYAGE 1, PASI 75 and PASI 90 were 76.3% and 87.8%, respectively, at 48 weeks. Similar outcomes were obtained in our study, where 88% of patients Our findings are also consistent with other real-life guselkumab studies [12,[15][16][17][18][19]. For example, an Italian study that had a mean ± SD baseline PASI score of 15.1 ± 6.1 showed that PASI 75, 90, and 100 were achieved by 95.6%, 73.9%, and 43.5% of patients at 44 weeks, respectively Likewise, our study achieved PASI 75, 90, and 100 in 88%, 72%, and 48% of patients at 52 weeks, respectively.…”

Section: Discussionsupporting

confidence: 93%

“…For example, an Italian study that had a mean ± SD baseline PASI score of 15.1 ± 6.1 showed that PASI 75, 90, and 100 were achieved by 95.6%, 73.9%, and 43.5% of patients at 44 weeks, respectively Likewise, our study achieved PASI 75, 90, and 100 in 88%, 72%, and 48% of patients at 52 weeks, respectively. Moreover, in another real-life study, 100% of patients had a PASI B 3 at 48 weeks [16]. Our study showed that 96% of patients achieved a PASI B 3 and 80% of patients achieved a PASI score of B 1 at 52 weeks.…”

Section: Discussionsupporting

confidence: 58%

See 1 more Smart Citation

Effectiveness and Safety of Guselkumab for the Treatment of Psoriasis in Real-World Settings at 52 weeks: A Retrospective, Observational, Multicenter Study from China

Yang

et al. 2022

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 93%

Section: Discussionsupporting

confidence: 58%

Effectiveness and Safety of Guselkumab for the Treatment of Psoriasis in Real-World Settings at 52 weeks: A Retrospective, Observational, Multicenter Study from China

Yang

et al. 2022

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

show abstract

“… 36 A 60-week, real-life, multicenter, retrospective study investigated the effectiveness, safety, and tolerability of guselkumab in psoriatic patients. 37 The mean baseline PASI reduced from 14.2 to 3.1 at week 12 and decreased to around 0 at weeks 36, 48, and 60. PASI 75, PASI 90, and PASI 100 have been achieved by 100%, 96.8%, and 83.9% of patients at week 60, respectively.…”

Section: Methodsmentioning

confidence: 93%

“…PASI 75, PASI 90, and PASI 100 have been achieved by 100%, 96.8%, and 83.9% of patients at week 60, respectively. 37 Another real-life study on guselkumab was represented by a retrospective chart review conducted in 79 patients with psoriasis who were prescribed guselkumab from November 2017 to June 2019 in Ontario, Canada. 38 Efficacy was assessed primarily through the body surface area (BSA) score, showing the complete clearance (BSA = 0%) for 35 patients (44.2%), an almost complete resolution (BSA < 1%) for 23 patients (29.1%), mild residual disease (BSA 2–3%) for 11 patients (13.9%), and low efficacy (BSA ≥3) for 10 patients (12.2%).…”

Section: Methodsmentioning

confidence: 99%

Guselkumab, Risankizumab, and Tildrakizumab in the Management of Psoriasis: A Review of the Real-World Evidence

Ruggiero¹,

Picone²,

Fabbrocini³

et al. 2022

CCID

View full text Add to dashboard Cite

Interleukin (IL)-23 inhibitors, guselkumab, risankizumab, and tildrakizumab, represent the latest class of biologics approved for the treatment of moderate-to-severe psoriasis. Since their approval numerous real-life studies were published on anti-IL-23 use in routine clinical practice. Indeed, real-life data are important to improve the dermatological decision-making process, including patients who are typically excluded from clinical trials, such as subjects suffering from several comorbidities, subjects on polypharmacy, as well as multifailure patients. Herein, we performed a comprehensive literature review about real-life data available on guselkumab, risankizumab, and tildrakizumab. Real-life data of anti-IL-23 seem to confirm the promising results of IL-23 shown by clinical trials, highlighting the efficacy and safety profiles of this new class of biologics also in clinical practice.

show abstract

“…Moreover, PASI reduction does not seem to be influenced by the presence of ≥3 comorbidities, BMI >30, the involvement of difficult-to-treat areas, smoking, and a previous failure to ≥2 biologic treatments (p > 0.05). 28 …”

Section: Discussionmentioning

confidence: 99%

Long-Term Efficacy and Safety of Guselkumab for Moderate to Severe Psoriasis: A 3-Year Real-Life Retrospective Study

Megna¹,

Potestio²,

Fabbrocini³

et al. 2022

PTT

View full text Add to dashboard Cite

Introduction Guselkumab safety and efficacy profiles in psoriasis have been showed by VOYAGE (1 and 2) trials. Although trial results have been already previously confirmed by real-life studies, long-term real-life data, and drug survival data about guselkumab are still poor. Patients and Methods We performed a 3-year retrospective study, with the aim of assessing guselkumab efficacy and safety profile in the management of plaque psoriasis in a real-life setting. Results Thirty-one patients completed the study. Both Psoriasis Area Severity Index (PASI) and Body Surface Area (BSA) statistically improved since week 16, and up to week 144 [PASI reduction from 16.4 ± 6.2 to 0.6 ± 0.9 (p < 0.0001) at week 144 while BSA from 33.2 ± 14.6 to 1.9 ± 1.4 (p < 0.0001)]. At week 12 PASI90 and PASI100 were achieved by 19 (61.3%) and 11 (35.4%) patients, respectively, as well as 24 (77.4%) and 18 (58.1%) subjects reached PASI 90 and PASI 100 at week 144. As regards the safety, no cases of injection site reaction, candida, serious AEs, malignancy, or major cardiovascular events were reported. Of note, mild AEs were collected with pharyngitis as the main one (7, 22.6%), followed by headache (5, 16.1%) and flu-like illness (5, 16.1%), all without requiring treatment discontinuation. Conclusion Our experience confirmed the efficacy and safety of guselkumab in daily clinical practice up to 3 years, suggesting this drug as an effective treatment option in psoriasis long-term management.

show abstract

Guselkumab for the treatment of psoriasis: a 60-week real-life multicenter retrospective experience

Cited by 12 publications

References 16 publications

Effectiveness and Safety of Guselkumab for the Treatment of Psoriasis in Real-World Settings at 52 weeks: A Retrospective, Observational, Multicenter Study from China

Effectiveness and Safety of Guselkumab for the Treatment of Psoriasis in Real-World Settings at 52 weeks: A Retrospective, Observational, Multicenter Study from China

Guselkumab, Risankizumab, and Tildrakizumab in the Management of Psoriasis: A Review of the Real-World Evidence

Long-Term Efficacy and Safety of Guselkumab for Moderate to Severe Psoriasis: A 3-Year Real-Life Retrospective Study

Contact Info

Product

Resources

About